How can we help protect high-risk patients against invasive pneumococcal disease?

VAXNEUVANCE®▼ (pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed))

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

VAXNUEVANCE can help protect your adult patients against 15 pneumococcal serotypes – click here for more

VAXNEUVANCE has been studied in patient groups at high-risk of pneumococcal disease - click here for more

VAXNEUVANCE®▼ (pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)) is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.¹

VAXNEUVANCE®▼ (pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)) is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.¹

Want to know more about how you can help protect your high-risk patients against pneumococcal disease?

Sign up for MSD email consent to receive the latest promotional information about VAXNEUVANCE.

References

VAXNEUVANCE Summary of Product Characteristics.
Platt HL, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults ≥50 years of age and older (PNEU-AGE). Vaccine 2022;40:162–172.
Mohapi L, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomised phase 3 study. AIDS 2022 Mar 1;36(3):373–382.
Hammit L, et al. Immunogenicity, safety, and tolerability of V114, a 15-valent pneumococcal conjugate vaccine, in immunocompetent adults aged 18–49 years with or without risk factors for pneumococcal disease: a randomised phase 3 trial (PNEU-DAY). Open Forum Infectious Diseases 2022;9(3), of ab605, https://doi.org/10.1093/ofid/ofab605.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.